Table 3. Adjusted odds ratios for completion of LTBI treatment by use of an interpreter.
1 N = 3,626.
| Characteristics | Adjusted Odds Ratio | 95% Confidence Interval | p-value |
|---|---|---|---|
| Interpreter | 1.28 | 0.97–1.69 | 0.08 |
| Time in the US (years) | 1.01 | 0.99–1.03 | 0.42 |
| Gender | |||
| Women | reference | ||
| Men | 1.14 | 0.95–1.35 | 0.15 |
| Enrollment reason 2 | |||
| Close contact | reference | ||
| Non-U.S.–born | 0.94 | 0.66–1.33 | 0.72 |
| Member of group with local LTBI prevalence ≥25%3 | 1.30 | 0.59–2.83 | 0.51 |
| HIV positive | 0.52 | 0.13–2.13 | 0.37 |
| Age (years) | 1.00 | 0.99–1.00 | 0.21 |
| Race/ethnicity | |||
| Asian | reference | ||
| Black/African American | 0.76 | 0.51–1.14 | 0.19 |
| Hispanic/Latino | 0.71 | 0.41–1.22 | 0.21 |
| White | 0.64 | 0.38–1.08 | 0.10 |
| Pacific Islander | 0.56 | 0.20–1.59 | 0.28 |
| Other | 0.91 | 0.69–1.21 | 0.52 |
| Unknown | 0.82 | 0.52–1.30 | 0.40 |
| Region of birth country | |||
| Africa | reference | ||
| America | 0.61 | 0.36–1.04 | 0.07 |
| Europe | 0.33 | 0.09–1.21 | 0.10 |
| Mediterranean | 0.49 | 0.35–0.70 | <0.001 |
| Pacific | 0.70 | 0.41–1.21 | 0.20 |
| Southeast Asia | 1.05 | 0.69–1.62 | 0.81 |
| Education 4 | |||
| No schooling | reference | ||
| Eighth grade or less | 1.02 | 0.78–1.35 | 0.87 |
| Some high school | 1.22 | 0.88–1.69 | 0.24 |
| High school graduate or GED | 1.34 | 0.96–1.87 | 0.09 |
| Trade school or associate degree | 1.58 | 0.81–3.08 | 0.18 |
| Some university/college | 1.49 | 0.95–2.33 | 0.08 |
| University/college graduate | 1.52 | 1.01–2.30 | 0.04 |
| Postgraduate schooling | 1.92 | 0.81–4.52 | 0.14 |
| Don’t know/refused | 0.46 | 0.14–1.47 | 0.19 |
| Housing status | |||
| Housed | reference | ||
| Experiencing homelessness | 0.49 | 0.24–0.98 | 0.045 |
| HIV | |||
| HIV uninfected | reference | ||
| Living with HIV infection | 1.49 | 0.62–3.60 | 0.37 |
| Diabetes | |||
| Without diabetes | reference | ||
| Living with diabetes | 1.04 | 0.69–1.57 | 0.85 |
| LTBI treatment initially accepted | |||
| 6- or 9-months isoniazid | reference | ||
| 4 months rifampin | 1.34 | 1.07–1.70 | 0.01 |
| 12 weeks- weekly doses isoniazid/rifapentine | 2.77 | 1.95–3.93 | <0.001 |
| Other regimens | 1.73 | 1.11–2.70 | 0.02 |
| Tuberculin Skin Test | 1.21 | 0.92–1.60 | 0.17 |
| QuantiFERON-TB Gold In-Tube | 1.15 | 0.92–1.44 | 0.21 |
1T-SPOT.TB test excluded due to >10% missing data
2 Participants enrolled due to having spent at least 30 days in a high-risk country were removed from this model due to a small number (n = 6)
3Populations with a prevalence of LTBI ≥ 25% varied by site (e.g., individuals experiencing homelessness or have a specific medical condition)
4Participants enrolled with an education level of “other” were removed from this model due to a small number (n = 4)